Ignite Creation Date:
2024-10-25 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06647862
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-16
Brief Title:
IMM01Azacitidine VS Placebo Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia CMML1-2
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Controlled Double-Blind Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of IMM01 Timdarpacept in Combination With Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia CMML1-2
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a randomized controlled double-blind multicenter phase Ⅲ clinical study to evaluate the efficacy of IMM01timdarpacept in combination with azacitidine versus placebo in combination with azacitidine in patients with newly diagnosed chronic leukemia monocytic CMML1-2Primary endpoint are Complete remission rate and Overall survival
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None